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Abstract: Sea snake envenomation is a serious occupational hazard in tropical waters.  
In Malaysia, the beaked sea snake (Hydrophis schistosus, formerly known as  
Enhydrina schistosa) and the spine-bellied sea snake (Hydrophis curtus, formerly known as 
Lapemis curtus or Lapemis hardwickii) are two commonly encountered species. Australian 
CSL sea snake antivenom is the definitive treatment for sea snake envenomation; it is 
unfortunately extremely costly locally and is not widely available or adequately stocked in 
local hospitals. This study investigated the cross-neutralizing potential of three regionally 
produced anti-cobra antivenoms against the venoms of Malaysian H. schistosus and  
H. curtus. All three antivenoms conferred paraspecific protection from sea snake venom 
lethality in mice, with potency increasing in the following order: Taiwan bivalent antivenom 
< Thai monocled cobra monovalent antivenom < Thai neuro polyvalent antivenom (NPAV). 
NPAV demonstrated cross-neutralizing potencies of 0.4 mg/vial for H. schistosus venom 
and 0.8 mg/vial for H. curtus, which translates to a dose of less than 20 vials of NPAV to 
neutralize an average amount of sea snake venom per bite (inferred from venom milking). 
The cross-neutralization activity was supported by ELISA cross-reactivity between NPAV 
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and the venoms of H. schistosus (58.4%) and H. curtus (70.4%). These findings revealed the 
potential of NPAV as a second-line treatment for sea snake envenomation in the region. 
Further profiling of the cross-neutralization activity should address the antivenomic basis 
using purified toxin-based assays. 
Keywords: sea snake; Hydrophis schistosus; Enhydrina schistosa; Hydrophis curtus; 
Lapemis hardwickii; antivenom; cross-neutralization; cross-reactivity 
 
1. Introduction 
Sea snake envenomation affects individuals involved in sea water activities, including swimmers, 
divers and particularly fishermen. Sea snake venoms are highly lethal; the envenomation can result in 
rapid death through neuromuscular paralysis and/or rhabdomyolysis, which leads to acute kidney injury. 
The wide distribution of sea snakes in the warm coastal waters makes sea snake envenomation an 
occupational health hazard for fisheries-related workers. In Malaysia, cases have been reported 
sporadically but are not uncommon [1,2]. There are more than 10 species of sea snakes in the  
Malaysian waters, and of these, the beaked sea snake (Hydrophis schistosus, previously known as  
Enhydrina schistosa) and spine-bellied sea snake (Hydrophis curtus, previously known as  
Lapemis curtus or Lapemis hardwickii) (see [3] for the latest systematics of these hydrophiid sea snakes) 
are the most commonly encountered species, particularly the former because it is often entangled in 
fishing nets and hauled in with the catch. Mishaps happen as the fishermen try to remove them from the 
nets [4]. These bites, in contrast to cobra and viper bites, are relatively painless and cause no remarkable 
local inflammation even as the toxins are insidiously absorbed and effectively distributed throughout the 
systemic circulation, causing rapid death if treatment is not sought in time. 
To date, the only indicated specific antidote for sea snake envenomation is Australian CSL sea snake 
antivenom. Unfortunately, that antivenom is extremely expensive locally (costing approx. 3000 USD 
per vial in Malaysia, with several vials often required for effective treatment). It is also a product that 
demands extreme care in transport and storage (the antivenom is in a perishable liquid form, needing 
constant cold storage). In addition to the unpredictable occurrence of bites, the antivenom is not widely 
available or adequately stocked in all Malaysian hospitals. In view of the restricted market demand and 
commercial difficulty faced by antivenom producers globally [5], there is also concern about whether 
sea snake antivenom production would be sustainable and sufficient to supply other countries, including 
Malaysia. Hence, a practical approach to optimizing the country’s treatment protocol would be searching 
for an alternative (or second-line) antivenom of choice, preferably based on the extended neutralization 
spectrum of a heterologous antivenom, which is more commonly stocked in local hospitals. The 
proposed strategy could be difficult, though, as snake venom toxins are highly variable between species; 
for instance, although neurotoxins are known to present in the venoms of sea snakes and cobras, there 
are substantial differences in their subtypes and mechanisms [6]. Nevertheless, previous studies have 
shown that some antivenoms can confer cross-neutralization effects on specific venom toxicities of 
heterologous species in animal studies, presumably due to the common antigenic properties of different 
venoms [7–9]. Earlier reports by Minton [10] and Khow et al. [11] suggested that Thai anti-cobra 
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antivenom (old batches, immunoglobulin form unspecified in [10], F(ab')2 in [11]) could neutralize  
the venoms of Enhydrina schistosa (synonymized as H. schistosus; unspecified source) and  
Lapemis hardwickii (synonymized as H. curtus; sourced from Japan Snake Institute), respectively. 
However, there is still a lack of systematic characterization and standard quantitation details for  
cross-neutralization efficacy and potency, as well as validation using the current commercially available 
and clinically used Thai antivenoms (produced by Queen Saobhava Memorial Institute), which are  
also manufactured with a revised WHO-endorsed method [12]. This study aims to investigate the  
cross-neutralization profile of two common Malaysian sea snake venoms by regionally produced  
anti-elapid antivenoms (with anti-cobra components), with mice as the experimental envenomation model. 
2. Experimental Section 
2.1. Venoms and Antivenoms 
Venoms were milked individually from adult H. schistosus and H. curtus collected from the 
Northwestern waters of Peninsular Malaya by one of the authors (CHT) into sterile polystyrene 
containers and lyophilized later. The venoms of two sea kraits (Laticauda laticaudata and  
Laticauda semifasciata) used for lethality comparison were obtained from Miami Serpentarium  
(Punta Gorda, FL, USA), and the venoms of Naja kaouthia and Calloselasma rhodostoma used in ELISA 
were obtained from Latoxan (Rosans, France). The antivenoms used were as follows: Taiwan bivalent 
antivenom for Naja atra and Bungarus multicinctus (batch: FN10001, expiry: 31 March 2016, 
manufacturer: Taiwan Central for Disease Control, Taipei, Taiwan); Thai monovalent antivenom for 
Naja kaouthia (batch: NK00310, expiry: 9 August 2015) and neuro polyvalent antivenom for  
Naja kaouthia, Ophiophagus hannah, Bungarus candidus and B. fasciatus (batch: NP00109; expiry:  
5 October 2014, manufacturer: Queen Saovabha Memorial Institute, Bangkok, Thailand). The antivenoms 
were purified equine F(ab')2 products and weighed 0.9–1.0 g each vial. They were diluted in 10 mL 
saline per vial according to the manufacturers’ recommendations, to a concentration of 90–100 mg/mL. 
2.2. Animals Use and Supply 
Mice used in this study were of albino ICR strain, 4–5 weeks old, male, weighing 20–25 g, and were 
supplied by the Animal Experimental Unit, University of Malaya. The protocol of experimental animal 
use in this study was based on the guidelines given by CIOMS [13] and the use of animals was approved 
by the Institutional Animal Care and Use Committee of the University of Malaya (Ref: 2014-09-11/ 
PHAR/R/TCH). 
2.3. Lethality Study 
Sea snake venoms were administered at a total volume of 100 μL via intravenous (via tail caudal 
vein), intramuscular (via quadriceps) or subcutaneous (via loose skin over the neck) route into albino 
ICR strain mice (20–25 g) at various doses (n = 4 per dose). The survival ratio for mice at each dose was 
recorded after 48 h of observation, in which the mice were given full access to food and water  
ad libitum. Median lethal doses of the venoms were determined for the different routes of administration 
using the Finney’s probit analysis method [14] (see Section 2.6). 
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2.4. Neutralization Study 
2.4.1. Preincubation Neutralization 
Neutralization of lethality was conducted as described by Tan et al. [9]. A lethal challenge dose 
constituting 2.5 or 5.0 LD50 of sea snake venom was preincubated at 37 °C with various dilutions of 
antivenom in normal saline for a total volume of 200 µL. The mixture was then centrifuged  
at ×10,000 g, and the supernatant was injected into the caudal vein of the mice (n = 4 per dose of 
antivenom). The number of mice that survived after 48 h was recorded for antivenom efficacy and 
potency estimations (see Section 2.6). 
2.4.2. Challenge-Rescue Neutralization 
Mice were subcutaneously envenomed with 2.5 LD50 of sea snake venom. Based on the result of the 
preincubation neutralization study (Section 2.4.1), the antivenom with the highest efficacy was injected 
intravenously into the experimentally envenomed mice (at different dilutions) via the caudal vein 10 min 
later. The number of mice that survived after 48 h was recorded for antivenom efficacy and potency 
estimations (see Section 2.6). 
2.5. Immunological Cross-Reactivity Study 
Immunological cross-reactivities between sea snake venoms and antivenom were examined with an 
indirect enzyme-linked immunosorbent assay modified from that used by Tan et al. [15]. The venoms 
of Naja kaouthia and Calloselasma rhodostoma were used for comparison with the sea snake venoms. 
In brief, immunoplate wells were precoated overnight with 5 ng of venom antigens (H. schistosus,  
H. curtus, Calloselasma rhodostoma, Naja kaouthia) at 4 °C. The plate was then flicked dry and rinsed 
five times with Tris-buffered saline with 0.5% Tween®20 (TBST). One hundred microliters of 
appropriately diluted antivenom (1:6000) was added to each antigen-coated well, followed by incubation 
for 1 h at room temperature. After washing the plate five times with TBST, 100 µL of appropriately 
diluted horseradish peroxidase-conjugated antihorse-IgG (Jackson ImmunoResearch Inc., West Grove, 
PA, USA) in TBST (1:8000) was added to the well and incubated for another hour at room temperature. 
The excess components were removed by washing five times with TBST. A hundred microliters of 
freshly prepared substrate solution (0.5 mg/mL o-phenylenediamine and 0.003% hydrogen peroxide in 
0.1 M citrate-phosphate buffer, pH 5.0) was added per well. The enzymatic reaction was allowed to take 
place in the dark for 15 min at room temperature. The reaction was subsequently terminated by adding 
50 µL of 12.5% sulfuric acid, and the absorbance at 492 nm was read against the blank using an  
ELISA reader (SUNRISE-TECAN Type Touch Screen F039300, Tecan, Männedorf, Switzerland).  
All experiments were performed in triplicate. 
2.6. Statistical Analysis 
Antivenom effectiveness was expressed as a median effective dose (ED50, the amount of reconstituted 
antivenom in µL that produces 50% survival in the animals tested), effective dose ratio (ER50, the amount 
of venom neutralized per mL of antivenom at which 50% of envenomed mice survived), as well as 
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“potency” (P, the amount of venom that is completely neutralized by a unit volume of antivenom, 
calculated according to Morais et al. [16]). The neutralization potency (P) is theoretically unaffected by 
the challenge dose and also serves as an indicator for comparing “neutralizing capability” between 
different antivenoms for a specific test venom. The median lethal dose (LD50), median effective dose 
(ED50), effective dose ratio (ER50) and the 95% confidence intervals (C.I.) were calculated using the 
probit analysis method used by Finney (1952) with BioStat 2009 analysis software (AnalystSoft Inc., 
Vancouver, Canada). The statistical analysis for the ELISA assay was conducted using SPSS (Version 
18.0, SPSS Inc., Chicago, IL, USA). The data (expressed as mean ± S.D.) were analyzed using one-way 
ANOVA, with Tukey’s post hoc multiple-comparison test, with p < 0.05 as the significant threshold. 
3. Results and Discussion 
All four sea snake venoms exhibited highly potent lethality in mice (Table 1), especially for the two 
common species in Malaysia: Both H. schistosus and H. curtus venoms possess LD50 < 0.1 µg/g. This 
indicates that the bites from these species, though they appear to be under-reported, should be taken very 
seriously by local health authorities. There are no significant differences (p > 0.05) noted in LD50 values 
between the three routes for envenoming (intravenous, intramuscular and subcutaneous), indicating that 
the sea snake venoms share a near-complete systemic absorption from the subcutaneous site of a snake 
bite. This is likely because the principal lethal toxins of sea snake venoms consist mainly of low 
molecular mass toxins (α-neurotoxins and phospholipases A2) [17] that are able to cross barrier 
membranes more effectively (better absorption) like cobra venom toxins [18]. Additionally, in sea snake 
bites, there is very minimal interaction between the local tissue and toxins (virtually no local tissue 
inflammation or necrosis) to retain the venom in situ [4]. This is in contrast to some Viperidae venoms 
which can show exceptionally low systemic bioavailability from a non-vascular injection site [19]. 
Table 1. Comparison of median lethal doses (LD50) of four sea snake venoms via different 
routes of administration into mice. 
Venom LD50 i.v. (µg/g) LD50 i.m. (µg/g) LD50 s.c. (µg/g) 
Hydrophis schistosus (Malaysia) 0.07 (0.05–0.09) 0.10 (0.08–0.12) 0.09 (0.06–0.14) 
Hydrophis curtus (Malaysia) 0.11 (0.07–0.17) 0.18 (0.12–0.27) 0.18 (0.17–0.18) 
Laticauda laticaudata 0.10 (0.08–0.12) - - 
Laticauda semifasciata 0.22 (0.15–0.34) - - 
i.v.: intravenous; i.m.: intramuscular; s.c.: subcutaneous; -: not determined. Units expressed as µg reconstituted 
venom per g mouse body weight. 
Since the neurotoxins (NTX) in H. schistosus venom are typically the short-chain type,  
cross-neutralization was first investigated using the Taiwan bivalent antivenom (TBAV), as Naja atra 
venom, one of the venoms used to raise the antivenom, consists mainly of short-NTX [20]. Using the 
antivenom-venom preincubation method, TBAV was found to be only weakly effective, with potency 
values of 0.016 mg/mL and 0.019 mg/mL for cross-neutralizing the venoms of H. schistosus and  
H. curtus, respectively, in mice (Table 2). The Thai Naja kaouthia monovalent antivenom (NKMAV) 
appeared to be more effective than TBAV in this regard (Table 2), with potency values approximately 
twice that of TBAV, even though Thai cobra venom is known to consist mainly of long α-neurotoxins. 
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These findings suggest that NKMAV may cross-react more substantially with the sea snake venoms. 
This supports an earlier report that Thai cobra long NTX-specific F(ab')2 cross-reacted with H. curtus 
venom [11], although the major NTX in sea snake venom is of the short NTX subtype [21]. The new 
polyvalent antivenom (neuro polyvalent antivenom, NPAV) produced by QSMI, which targets 
neurotoxic envenomation, showed a distinctively higher neutralizing potency, approximately twice that 
of NKMAV and four times that of TBAV, at doses standardized according to the respective guidelines 
for clinical use. Cross-neutralization by NPAV was also observed for sea krait (Laticauda sp.) venoms, 
which mainly comprise NTX of the short-chain type called erabutoxins [22]. In comparison with 
NKMAV, the apparently higher potency observed in NPAV in cross-neutralizing H. schistosus and  
H. curtus venoms could be due to synergistic cross-reacting effects from the polyvalent F(ab')2 against 
toxin components originating from other elapids, in particular possible neutralization of sea snake basic 
PLA2 in addition to the neurotoxins. A previous study [23] demonstrated that prior administration  
(10 min) of CSL tiger snake antivenom into the chick biventer cervicis nerve-muscle preparation was 
able to attenuate the neuromuscular blockade effect of the venoms of several sea snakes, except that 
produced by E. schistosa (synonymized as H. schistosus). The current in vivo study indicated that the 
antigenic properties of H. schistosus venom may be closer to that of the Naja cobra than the tiger snake. 
The cross-neutralization phenomenon is also supported by the immunological cross-reactivity result, 
where ELISA cross-reactivities between NPAV with H. schistosus and H. curtus venoms were shown 
to be 58.4% and 70.4% against blank, respectively (Figure 1). Comparatively, the ELISA reactivity of 
NPAV with the homologous N. kaouthia venom was high (103.3% against blank). The data indicate that 
the sea snake toxins have some degree of binding avidity toward NPAV, although the ELISA  
cross-reactivity values are not necessarily congruent or in proportion with the neutralizing potency 
against the different venoms. In contrast, the absorbance value for C. rhodostoma venom (14.4% against 
blank) is remarkably low, representing non-specific binding between venom proteins and NPAV without 
effective neutralizing activity. 
The cross-neutralizing effectiveness of NPAV was further tested in an experimental envenomation 
model, where different doses of NPAV were administered intravenously into mice that were 
subcutaneously pre-envenomed with 2.5 LD50 of H. schistosus or H. curtus venom. NPAV was proven 
effective in vivo for neutralizing both Malaysian sea snake venoms in the experimental envenomation 
model (Table 2). From the experience of venom milking (using the method of induced biting through  
a film), we estimate the average H. schistosus venom yield per bite to be 6.1 ± 3.7 mg (n = 22,  
range 2–12 mg, adult snake > 1 m) and average H. curtus venom amount per bite to be approximately 1 mg 
(n = 3, range 0.7–1.2 mg, adult snakes of approximately 1 m). Based on the potencies (Table 2)  
translated into 0.4 mg/vial and 0.8 mg/vial of NPAV for H. schistosus and H. curtus venoms 
respectively, a total of 10–20 vials of NPAV may be required for neutralization of the venom injected 
per bite. In cobra envenoming, this is considered an acceptable amount for antivenom dosage; the initial 
dose is typically 10 vials, followed by additional doses as required clinically [24]. 
 
Toxins 2015, 7 578 
 
Table 2. Cross-neutralization by paraspecific antivenoms against the lethal effect of selected sea snake venoms in mice. 
Venom 
TBAV (preincubation) NKMAV (preincubation) NPAV (preincubation) NPAV (challenge-rescue) 
ED50 
(µL) 
ER50  
(mg/mL) 
P 
(mg/mL) 
ED50 
(µL) 
ER50 
(mg/mL) 
P 
(mg/mL) 
ED50 
(µL) 
ER50 
(mg/mL) 
P 
(mg/mL) 
ED50 
(µL) 
ER50 
(mg/mL) 
P  
(mg/mL) 
Hydrophis 
schistosus 
141.36 
0.027  
(0.019–0.035) 
0.016 89.89 
0.045  
(0.032–0.058) 
0.027 100.00 
0.074  
(0.053–0.095) 
0.059 70.68 
0.070  
(0.047–0.109) 
0.042 
Hydrophis 
curtus 
200.00 
0.032  
(0.021–0.050) 
0.019 89.89 
0.070  
(0.045–0.109) 
0.042 125.00 
0.092  
(0.059–0.143) 
0.074 70.68 
0.143  
(0.135–0.143) 
0.086 
Laticauda 
laticaudata 
- - - - - - 75.00 
0.075  
(0.060–0.090) 
0.045 - - - 
Laticauda 
semifasciata 
- - - - - - 50.00 
0.253  
(0.173–0.391) 
0.15 - - - 
TBAV: Taiwan bivalent antivenom (for Naja atra and Bungarus multicinctus); NKMAV: Thai Naja kaouthia monovalent antivenom; NPAV: Thai neuro polyvalent antivenom.  
ED50: median effective dose, defined as the volume of reconstituted antivenom that protects 50% of mice from death; ER50: Effective dose ratio, defined as amount of venom neutralized 
per mL antivenom at which 50% of envenomed mice survived; P: Potency, defined as amount of venom neutralized per mL antivenom in total (presumably 100% survival conferred) [16]. 
Parentheses indicate the 95% C.I.; -: not determined. All venom doses used in neutralization study = 2.5 LD50, except in pre-incubation method for NPAV where 5 LD50 of H. schistosus 
and H. curtus venoms were used. The venom challenge doses (2.5 or 5 LD50) were all higher than the LD100 values of the corresponding venoms (1.2–1.6 LD50). 
 
Figure 1. Absorbance values from indirect ELISA indicating cross-reactivities between neuro polyvalent antivenom (NPAV) with venoms from 
Calloselasma rhodostoma, Hydrophis schistosus, Hydrophis curtus and Naja kaouthia. Values were expressed as mean of triplicates with 
standard deviation. Asterisks indicate significant difference between means (p < 0.05). 
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4. Conclusions 
The lethality of sea snake venoms does not vary significantly among routes of venom administration 
in mice, presumably due to effective absorption of principal toxins which are small in molecular size, 
such as neurotoxins and phospholipase A2. The anti-elapid antivenoms examined, especially NPAV, 
confer paraspecific neutralization against the lethal effect of sea snake venoms in mice. The potential of 
NPAV as a second-line treatment for sea snake envenomation, however, needs to be further substantiated 
with an antivenomic approach. The cross-neutralization effect can be profiled against purified sea snake 
principal toxins such as neurotoxins and phospholipases A2. Neurotoxins lead to flaccid paralysis while 
phospholipases A2 cause generalized myotoxicity [25,26]; the immunological interaction of NPAV with 
these toxins should be explored further for a better understanding of the paraspecific protective 
mechanism of NPAV against sea snake venoms. 
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